Etoposide 20 mg/ml Concentrate for Solution for Infusion

DRUG7 trials

Sponsors

GPOH gGmbH, Prinses Maxima Centrum voor Kinderoncologie B.V., Charite Universitaetsmedizin Berlin KöR, Centre Leon Berard, Institut Curie

Conditions

Acute Myeloid LeukemiaNeuroblastomaNewly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellularOcular conservative treatment for retinoblastomaPatients with High Risk NeuroblastomaRelapsed Acute Lymphoblastic Leukemia (ALL)atypical teratoid/rhabdoid tumours (ATRT)clear-cell and tanycytic or anaplastic ependymoma.

Phase 1

Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma: SIOPEN-Pilot01

RecruitingCTIS2023-509673-22-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Neuroblastoma

Start: 2024-12-02Target: 39Updated: 2025-09-11

Phase 2

RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome

RecruitingCTIS2024-514025-30-00

Institut CurieOcular conservative treatment for retinoblastoma

Start: 2021-03-25Target: 225Updated: 2024-05-31

SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

RecruitingCTIS2024-512222-28-00

Centre Leon Berardclear-cell and tanycytic or anaplastic ependymoma., myxopapillary, Newly diagnosed with an intracranial or spinal ependymoma (all WHO grades) including ependymoma variants: cellular +1

Start: 2015-06-02Target: 876Updated: 2024-12-09

Phase 3

An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy

RecruitingCTIS2022-501456-28-00

GPOH gGmbHatypical teratoid/rhabdoid tumours (ATRT)

Start: 2020-07-20Target: 301Updated: 2025-10-03

CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium Master Protocol

RecruitingCTIS2023-504999-25-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Acute Myeloid Leukemia

Start: 2023-07-14Target: 675Updated: 2025-08-14

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) “Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy

RecruitingCTIS2024-514917-36-00

Institut Gustave RoussyPatients with High Risk Neuroblastoma

Start: 2024-11-21Target: 719Updated: 2025-01-17

International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020

Not yet recruitingCTIS2023-509392-17-00

Charite Universitaetsmedizin Berlin KöRRelapsed Acute Lymphoblastic Leukemia (ALL)

Target: 765Updated: 2025-12-15